Kyle Gano, Chief Business Development Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 32,408 shares at $103.99 ($3.3M) on 2023-02-08, disclosed to the SEC on 2023-02-08.
Seasonal sale ($3.3M) by Chief Business Development Officer — this insider has traded NBIX in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $105.64 | 1,600 | $169K | 5.1% |
| 2 | $102.29 | 1,623 | $166K | 5.0% |
| 3 | $102.29 | 1,623 | $166K | 5.0% |
| 4 | $102.41 | 12,801 | $1.3M | 39.4% |
| 5 | $102.41 | 12,801 | $1.3M | 39.4% |
| 6 | $103.99 | 980 |
| $102K |
| 3.1% |
| 7 | $103.99 | 980 | $102K | 3.1% |
| Total | $102.65 avg | 32,408 | $3.3M | 100% |
| Filing → |
| NBIX | SELL | 2025-02-14 | $598K | — | Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $471K | — | Filing → |